Kymera Therapeutics Shares Surge on Promising Trial Results

Kymera Therapeutics shares are trading higher after the company announced positive results from its BroADen Phase 1b trial for KT-621 in patients with atopic dermatitis, demonstrating significant improvements in clinical endpoints and safety.